Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9263589 | Diagnostic Microbiology and Infectious Disease | 2005 | 6 Pages |
Abstract
Meropenem and imipenem are often the drugs of choice for the treatment of infections due to multidrug-resistant Acinetobacter baumannii. The present study aimed at evaluating the interaction between meropenem and sulbactam through microdilution and checkerboard methods against 48 clinical isolates of A. baumannii collected from Brazilian hospitals. All the isolates presented elevated minimum inhibitory concentration (â¥2 μg/mL) to either meropenem or sulbactam. The checkerboard method with the combination of meropenem and sulbactam demonstrated 29.2% (14/48) synergism, 47.9% (23/48) partial synergism, 10.5% (5/48) additive, 6.2% (3/48) indifference, and 6.2% (3/48) antagonism (ΣFICmin = 0.09 and ΣFICmax = 8). Thus, combinations of meropenem and sulbactam may show synergism or partial synergism for most A. baumannii isolates. Further studies may help identify treatment options for patients with infections caused by these organisms, particularly with this combination, where both drugs have time-dependent activities and might be suitable for therapy optimization studies.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Carlos R.V. Kiffer, Jorge L.M. Sampaio, Sumiko Sinto, Carmen P. Oplustil, Paula C.M. Koga, Andréa C. Arruda, Philip J. Turner, Caio Mendes,